Indian pharmaceutical company making generic drugs, branded formulations and vaccines, with a significant US generics business.
Indian pharmaceutical company making generic drugs, branded formulations and vaccines, with a significant US generics business.
Earns from US generic drugs, sold mainly to wholesalers and pharmacy chains at competitive prices, and from branded medicines that Indian doctors prescribe. The US is its largest single market. The Patel family, with Chairman Pankaj Patel, is the promoter and controlling shareholder.
In one line: India's smaller Teva Pharmaceutical.
Moat: narrow (regulatory licence, scale, process know-how). FDA-approved manufacturing facilities and a broad generics pipeline built over decades of regulatory filings.
Headquarters: Ahmedabad, India · Founded: 1952 · Employees: 36,827
Size Zydus Lifesciences (ZYDUSLIFE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $12.8B, the 90th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,202 on 18 Nov 2026.
Performance Over six months the shares gained 18.0%, against +8.3% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 24.0% over the last twelve months (peer median +14.5%); the operating margin is 17.0% (peer median 21.5%).
Valuation It trades at 30.0× forward earnings against a peer median of 26.6× (9th most expensive of 19).
Capital Return on invested capital runs 2.0 points below its cost of capital (11.3% WACC).
Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹304B | ₹270B | ₹229B | ₹193B | ₹171B |
| Revenue growth | — | +18% | +19% | +13% | — |
| Gross profit | ₹150B | ₹134B | ₹114B | ₹86.3B | ₹68.0B |
| EBITDA | ₹71.9B | ₹71.9B | ₹65.8B | ₹50.7B | ₹34.1B |
| Net income | ₹41.8B | ₹50.4B | ₹45.3B | ₹38.6B | ₹19.6B |
| Free cash flow | n/a | -₹4.80B | ₹51.8B | ₹23.8B | ₹16.1B |
| Capital expenditure | n/a | ₹33.9B | ₹16.9B | ₹9.07B | ₹10.3B |
| Total debt | ₹140B | ₹125B | ₹32.2B | ₹8.04B | ₹11.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zydus Lifesciences ZYDUSLIFE.NS | $12.8B | +18% | +24% | 17% | 30.0× | n/a |
| Torrent Pharmaceuticals TORNTPHARM.NS | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZYDUSLIFE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.9% | +6.1% | 9th highest of 21 |
| 6-month return | +18.0% | +8.3% | 9th highest of 21 |
| Distance from 52-week high | -5.1% | -6.8% | 8th highest of 21 |
| Revenue growth (TTM) | +24.0% | +14.5% | 6th highest of 20 |
| Operating margin | 17.0% | 21.5% | 7th lowest of 20 |
| Forward P/E | 30.0× | 26.6× | 9th most expensive of 19 |
| ROIC minus cost of capital | -2.0 pp | +6.6 pp | 5th lowest of 20 |
| EV / EBITDA | 18.2× | 19.5× | 8th cheapest of 15 |
| Net debt / EBITDA | 1.2× | -0.1× | 4th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.8B | +18% | +24% | 17% | 30.0× | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% | +33.6% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% | +12.1% |
| Laurus Labs LAURUSLABS.NS | India | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% | +7.3% |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% | +5.4% |
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% | +12.6% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $11.6B | -4% | -19% | 19% | 40.7× | 24.9% | +6.8% |
| Mankind Pharma MANKIND.NS | India | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% | +18.1% |
| Ipsen IPN.PA | France | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% | +7.2% |
| Repligen RGEN | United States | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% | +15.0% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $14.9B | -7% | +14% | -43% | n/a | n/a | n/a |
| Yunnan Baiyao 000538.SZ | China | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% | +4.7% |
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% | +13.1% |
| TG Therapeutics TGTX | United States | $9.99B | +66% | +69% | 21% | 25.2× | 43.0% | +426.7% |
| Pharmaron Beijing 300759.SZ | China | $9.90B | +52% | +18% | 14% | 36.8× | n/a | n/a |
| Exelixis EXEL | United States | $16.7B | +37% | +9% | 40% | 17.7× | -3.8% | +18.6% |
| Ascendis Pharma A/S ASND | United States | $16.9B | +12% | +94% | 18% | 28.0× | 19.2% | +152.4% |
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |